本期信息
根据上海昊海生物科技股份有限公司发布的2025年度业绩快报，报告期内实现营收人民币247,301.23万元，同比下降8.33%。经调整后（扣除非经常性损益）净利润为人民币16,048.17万元，同比下降57.67%。公司管理层指出，人工晶状体产品市场需求和竞争压力加剧，叠加对相关商誉及无形资产计提减值，导致经营利润承压。
下个财报期展望
公告显示，随着2026年上半年将启动人工晶状体产品第二轮国家带量采购，可能进一步加剧行业竞争并对产品价格产生影响。
业务分项
公司人工晶状体业务在2025年度面临显著经营压力，主要源于进口品牌Lenstec销售单价和销量持续下行，同时国内同类产品增多、价格竞争加剧。报告期内，公司对深圳市新产业眼科新技术有限公司相关商誉计提约人民币14,000.00万元减值准备，并对美国子公司Aaren Scientific Inc.所持有的品牌无形资产计提约人民币2,498.00万元减值准备。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.